Table II.

Treatment‐emergent adverse events of any grade occurring in ≥15% of patients and grade 3 or higher adverse events occurring in >10% of patients.

n (%)	Any grade	Worst grade 3	Worst grade 4
Any	40 (100)	10 (25)	26 (65)
Pyrexia	34 (85)	5 (13)	0
Hypotension	22 (55)	5 (13)	0
Neutropenia	20 (50)	3 (8)	15 (38)
Fatigue	18 (45)	1 (3)	0
Confusional state	15 (38)	1 (3)	0
Constipation	15 (38)	0	0
Nausea	14 (35)	1 (3)	0
Anaemia	13 (33)	8 (20)	0
Headache	13 (33)	0	0
Neutrophil count decreased	13 (33)	4 (10)	9 (23)
Diarrhoea	11 (28)	1 (3)	0
Hypokalaemia	11 (28)	2 (5)	0
Hypophosphataemia	11 (28)	6 (15)	0
Thrombocytopenia	10 (25)	5 (13)	2 (5)
Tremor	9 (23)	1 (3)	0
Chills	8 (20)	0	0
Decreased appetite	8 (20)	0	0
Hypoxia	8 (20)	2 (5)	1 (3)
Vomiting	8 (20)	1 (3)	0
White blood cell count decreased	8 (20)	2 (5)	6 (15)
Arthralgia	7 (18)	0	0
Dyspnoea	7 (18)	1 (3)	0
Leukopenia	7 (18)	1 (3)	5 (13)
Aphasia	6 (15)	1 (3)	0
Cough	6 (15)	0	0
Dizziness	6 (15)	0	0
Hypogammaglobulinaemia	6 (15)	0	0
Hyponatraemia	6 (15)	2 (5)	0
Insomnia	6 (15)	0	0
Muscular weakness	6 (15)	1 (3)	0
Platelet count decreased	6 (15)	0	4 (10)
Somnolence	6 (15)	0	0
Tachycardia	6 (15)	1 (3)	0